Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ANVSNYSEAMERICAN:APHBTSE:ONC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$11.91+3.6%$10.39$5.42▼$22.49$131.07M1.59265,365 shs226,539 shsAPHBAmpliphi Biosciences$2.51-6.0%$0.00$0.15▼$1.37$84.01MN/A842,200 shs5,098 shsONCOncolytics BiotechC$1.43-2.1%C$1.44C$1.20▼C$4.49C$107.85M1.4978,062 shs22,910 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+14.21%+3.42%+1.59%-1.29%-27.32%ONCOncolytics Biotech+1.39%0.00%+5.80%-11.52%-8.75%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.2898 of 5 stars3.41.00.00.01.81.70.6APHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AONCOncolytics Biotech0.6482 of 5 stars3.50.00.00.01.30.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio2.75Moderate Buy$27.75133.10% UpsideAPHBAmpliphi BiosciencesN/AN/AN/AN/AONCOncolytics Biotech3.00BuyC$6.00319.58% UpsideCurrent Analyst RatingsLatest ANVS, SCLP, APHB, REDX, and ONC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.004/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AC$0.34 per share4.22C$0.37 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)Latest ANVS, SCLP, APHB, REDX, and ONC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.392.39APHBAmpliphi BiosciencesN/AN/AN/AONCOncolytics Biotech1.549.018.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APHBAmpliphi BiosciencesN/AONCOncolytics Biotech6.98%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio38.30%APHBAmpliphi BiosciencesN/AONCOncolytics Biotech6.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio611.01 million6.79 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableANVS, SCLP, APHB, REDX, and ONC HeadlinesSourceHeadlineKrystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 viruspharmaceutical-technology.com - April 23 at 9:08 AMOutrun Therapeutics announces launch with $10m seed fundingpharmaceutical-technology.com - April 18 at 7:38 AMBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiescarolinapublicpress.org - April 17 at 10:38 AMStocks in play: Oncolytics Biotech® Inc.ca.finance.yahoo.com - April 11 at 3:56 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAfinance.yahoo.com - April 11 at 8:38 AMTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024markets.businessinsider.com - April 10 at 6:01 PMOncolytics Biotech is undervalued, Raymond James sayscantechletter.com - April 5 at 3:37 PMOncolytics Biotech (TSE:ONC) Trading Up 10.7%marketbeat.com - April 4 at 10:46 AMClosing Bell: Oncolytics Bio down on Friday (ONC)theglobeandmail.com - March 16 at 10:14 AMFutures Retreat Sharplymsn.com - March 11 at 4:05 PMOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANfinanznachrichten.de - March 6 at 4:39 PMEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winningfinanznachrichten.de - March 6 at 4:39 PMA Preview Of Oncolytics Biotech's Earningsbenzinga.com - March 6 at 4:39 PMOncolytics Biotech Inc ONCmorningstar.com - March 2 at 6:22 PMReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipelinemarkets.businessinsider.com - February 15 at 9:24 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsfinance.yahoo.com - February 15 at 9:24 AMAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapiestheglobeandmail.com - February 14 at 2:36 PMUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024finanznachrichten.de - February 7 at 11:03 AMKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Virusesfinance.yahoo.com - January 31 at 8:47 PMOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 6 at 3:30 PMJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)markets.businessinsider.com - December 14 at 8:26 AMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinanznachrichten.de - December 7 at 8:30 AMOncolytics Provides Update on Pancreatic Cancer Program for Pelareorepfinance.yahoo.com - November 9 at 7:48 AMOncolytics Biotech's Earnings Outlookbenzinga.com - November 3 at 6:37 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Ampliphi BiosciencesNYSEAMERICAN:APHBAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Oncolytics BiotechTSE:ONCOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.